血液系统恶性肿瘤相关血栓形成合并血小板减少症患者的血小板输注与抗凝治疗:CAVEaT多中心前瞻性队列研究
该多中心前瞻性队列纳入2019年5月14日至2021年4月24日20个中心的105例血液系统恶性肿瘤、28天内发生静脉血栓栓塞症(VTE)且血小板<50×10⁹/L的患者,描述实践与结局。中位年龄64岁,中位初始血小板计数28×10⁹/L;28天死亡率15%,VTE进展8%,大出血7%,临床相关非大出血25%;仅30例(47%)高危血栓患者和2例(5%)低危血栓患者的处理符合国际血栓与止血学会(ISTH)指导。作者结论认为需随机数据指导最优管理。
要点
- 105例血液系统恶性肿瘤合并VTE且血小板<50×10⁹/L患者中,28天死亡率15%、VTE进展8%、大出血7%。
- 高危血栓患者中仅30/64例(47%)的处理符合ISTH指导,低危血栓患者中仅2/5例(5%)符合。
- 血小板输注阈值、抗凝剂量减低阈值与血栓进展或大出血风险之间未见明确关系。
核心结论
- 该数据集显示,严重血小板减少合并急性血栓形成患者的处理方式存在异质性,并确认该队列出血率高,而血栓进展率与更广泛癌症相关血栓形成人群相似。
- 需要随机数据来指导最优管理。
研究设计与样本
- 多中心前瞻性队列研究,纳入2019年5月14日至2021年4月24日来自20个中心的105例血液系统恶性肿瘤、28天内发生VTE且血小板<50×10⁹/L的患者。
主要发现
- 中位年龄64岁,中位初始血小板计数28×10⁹/L。
- 血栓类型:46%导管相关,11%下肢,33%肺栓塞(PE),10%其他部位。
- 64例高危血栓患者中30例(47%)的处理符合ISTH指导,低危血栓(导管相关或无症状亚段PE)患者中2例(5%)符合。
- 12例(11%)未接受抗凝治疗;28天时死亡率15%,8%经历VTE进展,7%经历大出血,25%经历临床相关非大出血。
- 放置4枚下腔静脉滤器,其中2枚 later removed;中位输注血小板单位数为5(范围0-53);27%的患者在28天内改变管理策略。
关键数值与推荐
- 高危血栓患者中30/64例(47%)的处理符合ISTH指导。
- 低危血栓(导管相关或无症状亚段PE)患者中2/5例(5%)的处理符合ISTH指导。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) in patients with thrombocytopenia represents a complex management challenge. OBJECTIVES: To describe practice, document outcomes, and compare management to national guidelines. METHODS: We present a prospective multicenter cohort of 105 patients with hematological cancer, VTE within 28 days, and platelets <50 × 109 /L from May 14, 2019 to April 24, 2021 from 20 sites. RESULTS: Median age was 64 and median initial platelet count 28 × 109 /L. Thromboses were: 46% catheter-associated, 11% lower limb, 33% pulmonary emboli (PE), and 10% other sites. Management was according to International Society on Thrombosis and Haemostasis (ISTH) guidance in 30 (47%) of 64 patients with high-risk thrombosis and 2 (5%) of low-risk thrombosis (catheter-associated or asymptomatic subsegmental PE). Twelve patients (11%) received no anticoagulation. At 28 days mortality was 15%, 8% experienced VTE progression, 7% experienced major bleeding, and 25% experienced clinically relevant non-major bleeding. Four inferior vena cava filters were placed, two were later removed. The median number of platelet units transfused was 5 (range 0-53). Twenty-seven percent of patients had a change of management strategy by 28 days. There was no clear relationship among platelet transfusion threshold, anticoagulant dose reduction threshold, and risk of thrombosis progression or major bleeding. CONCLUSIONS: This data set demonstrates the heterogeneity of approaches used in patients presenting with severe thrombocytopenia and acute thrombosis and confirms the high rates of bleeding in this cohort with thrombosis progression rates similar to the wider cancer-associated thrombosis population. Randomized data is required to inform the optimal management.
引用
- Booth S, Desborough M, Curry N, et al. Platelet transfusion and anticoagulation in hematological cancer-associated thrombosis and thrombocytopenia: The CAVEaT multicenter prospective cohort. J Thromb Haemost. 2022. PMID: 35505495. doi:10.1111/jth.15748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。